Pliant Therapeutics Inc. (PLRX) Appoints Katharine Knobil to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors
September 15, 2022 8:00 AM EDTSOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Dr. Katharine Knobil to its Board of Directors, effective immediately.
I would like to extend a warm welcome to Kate whose global clinical development and strategic leadership experience, including her training as a pulmonologist, aligns perfectly with Pliant as we evolve into a late-stage biotechnology company, said Bernard Coulie, M.D., Ph.D., President and Chief Executive... More
